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TAVR Assessed With CMR
A New Piece in a Puzzle?*Javier Sanz, MD, George Dangas, MDM yocardial damage after transcatheteraortic valve replacement (TAVR) may becommon and herald a worse prognosis
(1,2). In this issue of the Journal, Kim et al. (3) report
on the incidence of new, ischemic-type, myocardial
late enhancement (LE) in patients undergoing
TAVR. They also compare LE with changes in serumSEE PAGE 349concentrations of high-sensitivity cardiac troponin T
(hs-cTnT) and creatine kinase-myocardial band. The
authors performed cardiac magnetic resonance imag-
ing examinations in 61 patients at a median of 3 days
before and 6 days after TAVR and measured cardiac
enzymes at baseline and on days 1, 2, and 3 after
the procedure. Even before TAVR, ischemic-type LE
was present in 42 patients (70%), and new areas
(excluding apical scar in transapical access) devel-
oped in 11 patients (18%) involving a median of 3.7 g
or 1.8% of left ventricular (LV) mass. None of the pa-
tients experienced clinical signs or symptoms of a
new infarct. New LE areas were focal, with a subendo-
cardial, transmural, or intramyocardial distribution.
There were no signiﬁcant differences between pa-
tients with or without new LE in terms of baseline
characteristics, aortic stenosis severity, imaging ﬁnd-
ings, or procedural technique, with the exception of
more severe renal impairment in the patients with
new LE. However, although LV ejection fraction* Editorials published in the Journal of the American College of Cardiology
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disclose.remained unchanged in the LE– group, it was
decreased signiﬁcantly in the LEþ group (from 56 
14% to 45  15%; p ¼ 0.001). With respect to cardiac
enzymes, median hs-cTnT was >99th percentile in
46 patients (75%) at baseline and increased to >99th
percentile after TAVR (to a median maximal concen-
tration of 307 ng/l) in all cases. Similarly, creatine
kinase-myocardial band was elevated at baseline
and increased post-TAVR to a median peak concen-
tration of 21.0 U/l. There was no signiﬁcant associa-
tion between enzyme changes and LE development,
except in the transfemoral access subgroup.
Kim et al. (3) should be congratulated for im-
proving our understanding of myocardial damage in
patients with severe aortic stenosis, both before and
after TAVR. It is most striking that the vast majority
of these patients have low-grade, ongoing myocar-
dial damage (by LE and/or biomarkers), suggesting
that such injury is chronic and directly related to
the pathophysiology of severe aortic stenosis, even
before any procedure. Indeed, LV hypertrophy and
low coronary perfusion pressure may render the
subendocardium vulnerable to ischemia during hy-
potensive episodes, which can happen at any time
and obviously during interventional procedures.
Autoimmune-mediated myocardial injury also might
play a role, as reported late after a coronary event
(4). Another important observation is that enzyme
elevation, regardless of LE development, was consis-
tently higher in the transapical access group. If we
accept the prognostic importance of myocardial
damage, then transapical TAVR should be reserved
strictly for those patients who absolutely cannot un-
dergo transarterial TAVR.
The development of new focal LE with a sub-
endocardial or transmural distribution is indeed con-
sistent with an ischemic injury. The absence of
signiﬁcant coronary stenoses in the corresponding
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359vessels in all but 1 patient with new LE, and the pres-
ence of 2 newLE areas in different territories in another
case suggest an embolic etiology. Although some of the
areas of new LE displayed a small rim of viable endo-
cardium, an embolic source is still possible, as
described after percutaneous coronary intervention
(5). Nonetheless, hypoperfusion in the setting of cor-
onary disease also may be contributory. Although the
coronary calcium score did not differ signiﬁcantly be-
tween groups, diffuse coronary disease burden, as
determined by intravascular ultrasound, has been
associated with myonecrosis after percutaneous cor-
onary intervention (6). The authors did not investigate
potential associations between new LE and angio-
graphic indices of disease extent, which could have
further strengthened (or challenged) the embolic
hypothesis.
When considering an embolic source, the calciﬁed
aortic valve is the obvious candidate. Although not a
statistically signiﬁcant ﬁnding (p ¼ 0.09), the dis-
tance from the aortic annulus to the left coronary
ostium was shorter in patients with new LE; thus,
embolism may be more likely in such patients. In
addition, balloon post-dilatation, which could pose
higher risk for embolization, was performed twice as
frequently in the LEþ group (although again, this
ﬁnding was not signiﬁcant). As mentioned by the
authors, calciﬁed debris embolizes into the coronary
arteries in experimental models of aortic valvulo-
plasty (7), but somewhat counterintuitively, the valve
calcium score did not differ between patients with
and without new LE. Nonetheless, procoagulant
tissue factor is abundant in stenotic valves (8) and
could theoretically lead to ongoing thrombus forma-
tion around the crushed native leaﬂets, or to in
situ thrombosis if embolized to the distal coronary
circulation.
Even though an embolic component for the de-
velopment of new areas of LE appears possible,
perhaps the most intriguing ﬁnding in this study was
the discrepancy between serum and imaging markers
of myocardial damage. Although the majority of pa-
tients had evidence of pre-procedural damage and all
experienced further elevations in cardiac enzymes
after TAVR, only 18% developed new LE. This obser-
vation is not trivial because LV ejection fraction
decreased exclusively in the new LE group, a ﬁnding
that can represent a link between TAVR-related
myocardial damage and impaired outcomes. One po-
tential explanation may be limitations of the LE
technique: minute infarcts might be missed, the
relatively small contrast dose used by the authors
may have led to slightly reduced sensitivity, and
diffuse (as opposed to localized) myocardial injury isnot identiﬁable with LE. However, this discrepancy
also argues against an embolic-only explanation for
the universally noted myocardial injury. Other po-
tential contributors include severe intraprocedural
hypotension and hypoperfusion (in the setting of
rapid pacing and balloon pre- and post-dilation, aortic
valve occlusion, concomitant coronary atheroscle-
rosis, and blunted myocardial perfusion reserve),
direct ventricular irritation from the intracavitary
wire, direct damage of the periannular myocardium,
or the development of intraprocedural valvular
regurgitation. Unfortunately, the authors did not
control for these factors, which could have provided
mechanistic insights.
Why then did some patients develop visible necro-
sis/scar, whereas others did not? Patients undergoing
TAVR experience new, acute injury superimposed on
chronic, ongoing damage. Thus, there may be a
threshold effect that makes the development of LE
more likely. An alternative explanation may be hinted
from some differences between the LE– and LEþ
groups, albeit mostly not signiﬁcant statistically.
Renal function was worse in the LEþ group (p¼ 0.01), a
factor linked to higher likelihood of periprocedural
injury in percutaneous coronary intervention (9).
Interestingly, the prevalence of diabetes, another
condition associated with increased cardiovascular
vulnerability and diffuse atherosclerosis, was almost
double in the LEþ group. The extent of prior myocar-
dial LE was smaller in patients developing new LE, as
was the burden of coronary disease as determined by
the calcium score. Conversely, prior surgical revascu-
larizationwas noted only in the LE– group. All together,
we may speculate that patients with more severe cor-
onary disease or prior myocardial damage may be
paradoxically less likely to develop new LE areas (from
embolism or other sources) perhaps because of the
protection granted by graft presence or prior episodes
of ischemic preconditioning. On the other hand, pa-
tients inherently susceptible to repeated myocardial
injury (e.g., those with renal insufﬁciency) and with-
out prior ischemic episodes may have fewer reserve
mechanisms to compensate for an acute insult and
thus develop new LE more easily.
In the study by Kim et al. (3), TAVR caused visible
perioperative myocardial damage in certain patients.
Understanding the underlying mechanisms will pro-
mote preventive strategies and possibly improve
outcomes. However, this should not be interpreted
as an exclusively TAVR-related shortcoming. Myo-
cardial damage also occurs during aortic balloon
valvuloplasty or surgical valve replacement (10),
2 procedures in which embolic events, hypotension,
and severe hypoperfusion take place as well. We
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360would encourage similar cardiac magnetic resonance
studies to be conducted in these interventional pro-
cedures. In addition, larger multicenter trials or reg-
istries with prolonged follow-up will be needed to
understand the implications and interplay between
cardiac enzyme release, development of new LE,
and reductions in LV ejection fraction. Finally, novel
cardiac magnetic resonance approaches for the detec-
tion of diffuse myocardial ﬁbrosis or intraproceduraldetection of embolic episodes with intracoronary
Doppler guidewires may help to clarify mechanisms of
myocardial damage during aortic valve intervention.
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